Entomopharm ApS Patent applications |
Patent application number | Title | Published |
20140342392 | OPTIMIZED INSECT-BASED EX VIVO MODEL FOR TESTING BLOOD-BRAIN BARRIER PENETRATION AND METHOD FOR EXPOSING INSECT BRAIN TO CHEMICAL COMPOUNDS - There is provided an ex-vivo insect screening model to determine blood-brain barrier penetration of different chemical compounds. The method comprises the steps: • Optionally anesthetizing the insect • Fixing the head of the insect • Dissecting out the brain of the insect head thereby removing the brain from its cuticle • Optinally removing the neural lamella of the brain • Treating the brain with a solution of the chemical compound • Washing anf homogenising or ultra sound disintegrating the brain • Determining the concentration of the chemical compound in the homogenised brain material and • Calculating the penetration of the chemical compound through the blood-brain barrier The concentration of the chemical compound is determined by LC/MS and the chemical compound can be a CNS drug. | 11-20-2014 |
20120122145 | INSECT-BASED EX VIVO MODEL FOR TESTING BLOOD-BRAIN BARRIER PENETRATION AND METHOD FOR EXPOSING INSECT BRAIN TO CHEMICAL COMPOUNDS - There is provided an ex-vivo insect screening model to accurately determine blood-brain barrier penetration of different chemical compounds in order to improve the compound screening procedures/processes in the early drug discovery process. This object offers many advantages relative to prior technologies since insect models are more reliable tools for the decision-making process than the existing in vitro models, and will speed up the drug screening process and reduce the late phase attrition rate. Moreover, it will reduce the number of mammals sacrificed during the drug discovery phase. | 05-17-2012 |
20120122144 | METHODS EMPLOYING INSECT MODELS FOR DETERMINING INTESTINAL ABSORPTION OF CHEMICAL COMPOUNDS - There is provided insect screening models to determine gastrointestinal absorption of different chemical compounds in vertebrates, and in particular humans, in order to improve the compound screening procedures/processes in the early drug discovery process. This offers many advantages relative to prior technologies since insect models are more reliable tools for the decision-making process than the existing in vitro models, and will speed up the drug screening process and reduce the late phase attrition rate. Moreover, it will reduce the number of mammals sacrificed during the drug discovery phase. | 05-17-2012 |
20120119081 | INSECT-BASED MODEL FOR PHARMACO-KINETIC STUDIES - There is provided a new methodology for initial assessment of compound PK. The invention is generally particular useful for efficient screening of and assessment of PK profiles of newly synthesized compounds in the early phase of drug discovery. | 05-17-2012 |